Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05076006 · ClinicalTrials.gov registry record · Phase 2
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
A Phase 2 study, sponsored by Emma Guttman.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT05076006 is a Phase 2 study that has completed, run by Emma Guttman. The registered enrollment target is 51 participants.
The verdict
NCT05076006, a Phase 2 study, has completed, sponsored by Emma Guttman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known as cicatricial alopecia (CA), in which hair follicles are irreversibly destroyed. CA leads to scarred areas, most commonly on the scalp, that cannot re-grow hair. Despite being a long-term condition, that often has significant impact on patients' well-being, available effective treatments for these diseases are lacking. In addition, the molecular abnormalities causing CA are largely unknown. The study team's research involves administrating patients a new investigational drug (a combined TYK/JAK inhibitor) which has been shown to be safe and well tolerated in clinical studies to date, and is being investigated in other conditions, such as AA. CA patients will be asked to provide small samples of skin and blood throughout the treatment period, to find out how they respond to the drug, and to attempt to better understand these diseases.
Interventions
- DRUG Placebo
- DRUG PF-06700841
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2021-05-19 |
| Est. Completion | 2023-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05076006
The ClinicalTrials.gov registry entry for NCT05076006 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emma Guttman, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05076006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05076006 about?
NCT05076006 is a clinical study titled "Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia". Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known as cicatricial alopecia (CA), in which hair follicles are irreversibly...
What is the current status of trial NCT05076006?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2021-05-19. Estimated completion is 2023-09-30.
What interventions are being tested in trial NCT05076006?
The interventions under investigation include: Placebo (DRUG), PF-06700841 (DRUG).
Who is sponsoring clinical trial NCT05076006?
This trial is sponsored by Emma Guttman, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.